Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma.
Gouda MA, Stephen B, Tian Y, Alshawa A, Onwugaje DOC, Albittar A, Yang Y, Zarifa A, Yilmaz B, Gurses S, Sprenger A, Derbala MH, Brink A, How JA, Moyers J, Piha-Paul SA, Hong DS, Meric-Bernstam F, Patel SP, Oliva IG. Gouda MA, et al. Among authors: how ja. J Immunother Precis Oncol. 2024 Nov 1;7(4):247-254. doi: 10.36401/JIPO-24-3. eCollection 2024 Nov. J Immunother Precis Oncol. 2024. PMID: 39524469 Free PMC article.
The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial.
How JA, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Yang F, Naing A. How JA, et al. Invest New Drugs. 2021 Jun;39(3):829-835. doi: 10.1007/s10637-020-01043-9. Epub 2021 Jan 7. Invest New Drugs. 2021. PMID: 33415580 Free PMC article. Clinical Trial.
Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report.
Batman S, Rauh-Hain JA, Grinsfelder MO, Harrison R, Avila M, Cun H, How JA, Tandon N, Wang X, Hinchcliff E, Jazaeri AA, Schmeler KM. Batman S, et al. Among authors: how ja. Case Rep Oncol. 2023 Apr 27;16(1):273-278. doi: 10.1159/000530154. eCollection 2023 Jan-Dec. Case Rep Oncol. 2023. PMID: 37123608 Free PMC article.
Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial.
How JA, Dang M, Lee S, Fellman B, Westin SN, Sood AK, Fleming ND, Shafer A, Yuan Y, Liu J, Zhao L, Celestino J, Hajek R, Morgan MB, Parra ER, Laberiano Fernandez CD, Arrechedera CA, Solis Soto LM, Schmeler KM, Nick A, Lu KH, Coleman R, Wang L, Jazaeri AA. How JA, et al. Med. 2024 Aug 15:100494. doi: 10.1016/j.medj.2024.07.022. Online ahead of print. Med. 2024. PMID: 39151421
Immuno-Oncology for Gynecologic Malignancies.
How JA, Patel A, Jazaeri AA. How JA, et al. Adv Exp Med Biol. 2021;1342:193-232. doi: 10.1007/978-3-030-79308-1_6. Adv Exp Med Biol. 2021. PMID: 34972966 Review.
Immuno-oncology for Gynecologic Malignancies.
How J, Patel A, Jazaeri A. How J, et al. Adv Exp Med Biol. 2020;1244:149-182. doi: 10.1007/978-3-030-41008-7_7. Adv Exp Med Biol. 2020. PMID: 32301014 Review.
36 results